Oric Pharmaceuticals (ORIC) Expected to Announce Quarterly Earnings on Tuesday

Oric Pharmaceuticals (NASDAQ:ORIC) is projected to issue its Q4 2025 results before the market opens on Tuesday, February 17th. Analysts expect Oric Pharmaceuticals to post earnings of ($0.33) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 11:30 AM ET.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.08. On average, analysts expect Oric Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oric Pharmaceuticals Stock Performance

Shares of NASDAQ ORIC opened at $9.99 on Friday. Oric Pharmaceuticals has a 52-week low of $3.90 and a 52-week high of $14.93. The stock has a 50 day moving average price of $9.86 and a 200 day moving average price of $10.87. The firm has a market capitalization of $972.93 million, a price-to-earnings ratio of -5.77 and a beta of 1.35.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ORIC. JPMorgan Chase & Co. raised their price objective on Oric Pharmaceuticals from $17.00 to $20.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Wedbush reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of Oric Pharmaceuticals in a research note on Tuesday, January 13th. HC Wainwright raised their price target on shares of Oric Pharmaceuticals from $19.00 to $23.00 and gave the company a “buy” rating in a research report on Friday, November 14th. Wall Street Zen lowered shares of Oric Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, November 23rd. Finally, Oppenheimer lifted their price target on Oric Pharmaceuticals from $12.00 to $15.00 and gave the stock an “outperform” rating in a report on Friday, November 14th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $19.90.

Insiders Place Their Bets

In other Oric Pharmaceuticals news, CEO Jacob Chacko sold 33,374 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total value of $302,368.44. Following the completion of the sale, the chief executive officer owned 581,711 shares in the company, valued at approximately $5,270,301.66. The trade was a 5.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Pratik S. Multani sold 10,720 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total transaction of $97,123.20. Following the transaction, the insider owned 68,149 shares in the company, valued at approximately $617,429.94. This trade represents a 13.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 54,814 shares of company stock valued at $496,615 over the last quarter. Company insiders own 6.82% of the company’s stock.

Institutional Trading of Oric Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Intech Investment Management LLC raised its stake in shares of Oric Pharmaceuticals by 53.1% during the 4th quarter. Intech Investment Management LLC now owns 26,606 shares of the company’s stock worth $218,000 after buying an additional 9,223 shares during the last quarter. Creative Planning increased its position in Oric Pharmaceuticals by 59.5% during the 3rd quarter. Creative Planning now owns 17,694 shares of the company’s stock worth $212,000 after purchasing an additional 6,599 shares in the last quarter. Jain Global LLC acquired a new position in shares of Oric Pharmaceuticals during the third quarter worth about $182,000. Jane Street Group LLC boosted its stake in shares of Oric Pharmaceuticals by 56.0% in the first quarter. Jane Street Group LLC now owns 31,198 shares of the company’s stock valued at $174,000 after purchasing an additional 11,198 shares during the period. Finally, DRW Securities LLC acquired a new position in shares of Oric Pharmaceuticals in the 4th quarter valued at approximately $157,000. Hedge funds and other institutional investors own 95.05% of the company’s stock.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.